Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Kensey Nash 2011 first quarter decreases 14% to $17.0 million

Kensey Nash Corporation , a medical device company primarily focused on regenerative medicine for a wide range of medical procedures, today reported the results for its first quarter ended September 30, 2010.

21 Oct 2010

Baxter third quarter net income increases 12% to $595 million

Baxter International Inc. today announced its financial results for the third quarter of 2010, and provided its fourth quarter and updated full-year 2010 financial outlook.

From Baxter International Inc. 21 Oct 2010

Nonprescription drug manufacturing and marketing costs increase: Kline

A number of costs associated with nonprescription drug manufacturing and marketing have increased over the past two and a half years. Certain material costs for plastic bottles and blister packs have risen by double digits during this time, increasing packaging expenses.

21 Oct 2010

Vascular Solutions acquires EXPRO Elite and MICRO Elite snare products from Radius

Vascular Solutions, Inc. today announced that it has acquired the assets related to the EXPRO Elite™ and MICRO Elite™ snare products from Radius Medical Technologies, Inc. and its subsidiary, Radius Medical, LLC. Vascular Solutions has been selling the EXPRO Elite™ and MICRO Elite™ snares in the U.S. under a distribution relationship with Radius since 2008, while in international markets Radius has been selling the products through a network of independent distributors.

21 Oct 2010

Victorian Government grants assist companies build global markets

The Brumby Labor Government is providing $410,000 in grants to help three Melbourne companies improve their global competitiveness, save money on production costs and create local jobs.

21 Oct 2010

FDA issues complete response letter for BYDUREON NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter regarding the New Drug Application (NDA) for BYDUREON™ (exenatide extended-release for injectable suspension).

21 Oct 2010

Genzyme third quarter revenue increases to $1.0 billion

Genzyme Corp. today reported third-quarter earnings growth driven by increased shipments of Cerezyme® (imiglucerase for injection). Patients in the United States began returning to normal dosing levels last month, and patients globally are expected to be able to do so this quarter. Earnings growth in the third quarter was also driven by strong revenue from Lumizyme™ (alglucosidase alfa) and cost reduction measures.

21 Oct 2010

Cipla launches generic Pirfenidone for IPF

Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers. Till now there is no approved treatment for IPF.

20 Oct 2010

Particle Sciences enters licensing, technology agreement with Solubest

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO and SoluBest have entered into a licensing and technology development agreement. Under the agreement, Particle Sciences will be the exclusive contract research provider in the U.S. for SoluBest's Solumer technology.

20 Oct 2010

Adamis acquires prostrate drug candidates from Colby Pharmaceuticals

Adamis Pharmaceuticals Corporation today announced the completion of the acquisition from Colby Pharmaceuticals of the remaining exclusive license agreements relating to two drug product candidates for the treatment of prostate cancer (PCa).

20 Oct 2010

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc. today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter of 2011 and to initiate a Phase 1 clinical trial by the first quarter of 2012.

19 Oct 2010

Novartis to implement Veeva CRM for global deployments

Veeva Systems announced today that Novartis Pharmaceuticals AG, a world leader in the research, development, manufacturing and marketing of products to protect and improve health and well-being, has chosen Veeva CRM® for various global deployments.

19 Oct 2010

Johnson & Johnson third quarter sales decrease 0.7% to $15.0 billion

Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.

19 Oct 2010

Althea installs INOVA H3-5 high-speed syringe filling line

Althea Technologies, Inc., a leading provider of development and manufacturing services for biopharmaceuticals and parenteral drug products, announced today that it has completed the installation of a new INOVA H3-5 high-speed syringe filling line.

19 Oct 2010

Tylenol batch recalled due to strange smell

Johnson and Johnson’s (J&J) commonly used over-the-counter painkiller Tylenol has been recalled again in some batches because of complaints of a musty or moldy odor in the product. The company is facing a U.S. congressional probe of quality control lapses in the past as well. The drugs recalled to date include the painkiller Motrin and allergy treatment Benadryl as well as this batch of 100,000 bottles of Tylenol.

18 Oct 2010

Goodwin enters new Biopharmaceutical Development and Manufacturing Agreement with multinational client

Goodwin Biotechnology, Inc., a full service contract biomanufacturing company, today announced that it has signed a new Biopharmaceutical Development and Manufacturing Agreement with a multinational biopharmaceutical client. According to the agreement, Goodwin will develop the process to manufacture a unique therapeutic monoclonal antibody conjugate for diagnostic imaging purposes.

18 Oct 2010

Bend Research extends 3-year agreement with Bristol-Myers Squibb

Bend Research Inc. a leading independent technology-based drug-formulation development and manufacturing organization, announced today it has extended its drug discovery enablement and development services agreement with Bristol-Myers Squibb Company, a global biopharmaceutical company.

18 Oct 2010

Scientists find unexpected function of cell's protein-making machinery

When cells make the proteins that carry out virtually every function of life, it's vital that the right things happen at the right times, and maybe more importantly that wrong things are stopped from happening at the wrong times.

18 Oct 2010

UK Intellectual Property Office issues patent for entinostat

Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced the UK Intellectual Property Office allowed application GB0907347.9 entitled N-(2-aminophenyl)-4-[N-(pyridine-3-YL)-methoxycarbonyl-aminomethyl]-benzamide (MS-275) polymorph B.

18 Oct 2010

New comprehensive program for medical electronic device designers

Canon Communications today announced the formation of a comprehensive program to assist designers, developers, and engineering managers involved in the design of electronics-based medical devices. The DesignMED conference and exposition is a collaborative project between the company's Medical Device Group-Medical Electronics Design (MED), EDN, and MD+DI-and its Event Division.

15 Oct 2010